Danaher Co. (NYSE:DHR) Holdings Increased by MJP Associates Inc. ADV

MJP Associates Inc. ADV lifted its stake in shares of Danaher Co. (NYSE:DHR) by 10.7% during the second quarter, Holdings Channel.com reports. The fund owned 6,041 shares of the conglomerate’s stock after purchasing an additional 582 shares during the period. MJP Associates Inc. ADV’s holdings in Danaher were worth $1,509,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in DHR. Austin Private Wealth LLC lifted its holdings in Danaher by 4.3% in the 2nd quarter. Austin Private Wealth LLC now owns 1,633 shares of the conglomerate’s stock valued at $408,000 after acquiring an additional 67 shares during the last quarter. Blue Zone Wealth Advisors LLC lifted its stake in Danaher by 18.7% during the second quarter. Blue Zone Wealth Advisors LLC now owns 14,849 shares of the conglomerate’s stock valued at $3,710,000 after purchasing an additional 2,337 shares during the last quarter. Fermata Advisors LLC bought a new stake in Danaher during the second quarter worth approximately $428,000. Curated Wealth Partners LLC grew its position in Danaher by 200.0% in the second quarter. Curated Wealth Partners LLC now owns 1,215 shares of the conglomerate’s stock worth $304,000 after buying an additional 2,430 shares during the last quarter. Finally, Thrive Wealth Management LLC increased its holdings in shares of Danaher by 1.1% in the second quarter. Thrive Wealth Management LLC now owns 6,134 shares of the conglomerate’s stock valued at $1,533,000 after buying an additional 64 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Royal Bank of Canada lifted their target price on Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. SVB Leerink lifted their price target on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group upped their price objective on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and lifted their target price for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. Finally, StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average price target of $276.88.

Insider Transactions at Danaher

In other Danaher news, CEO Rainer Blair sold 19,085 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $255.00, for a total transaction of $4,866,675.00. Following the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at $29,578,725. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Danaher news, CEO Rainer Blair sold 19,085 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $255.00, for a total transaction of $4,866,675.00. Following the transaction, the chief executive officer now owns 115,995 shares in the company, valued at $29,578,725. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The disclosure for this sale can be found here. Insiders have sold a total of 66,797 shares of company stock worth $18,039,944 in the last 90 days. 11.10% of the stock is owned by insiders.

Danaher Stock Down 0.2 %

NYSE DHR traded down $0.53 on Friday, reaching $268.11. The stock had a trading volume of 2,017,772 shares, compared to its average volume of 2,898,902. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The business has a 50 day moving average price of $257.31 and a 200 day moving average price of $252.45. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $198.59 billion, a price-to-earnings ratio of 45.44, a P/E/G ratio of 4.62 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.05 EPS. On average, analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.